Cardiovascular Diseases Clinical Trial
Official title:
Image Based Mobile System for Dietary Assessment and Coaching
Vignet partnered with The George Washington University Hospital to conduct a randomized control trial (RCT) with to evaluate the system's potential to improve health outcomes for patients with CVD. Results from the RCT have the potential to be applied to patients in other chronic disease contexts.
84 million American adults (>1 in 3) have cardiovascular disease, and cardiovascular disease
accounts for 1 of every 3 deaths in the United States and has been the number one cause of
deaths in every year since 1918. In addition, strokes, heart attacks, and uncontrolled
hypertension are sources of significant disability. However, with control of known
cardiovascular risk factors (i.e., smoking, body mass index, physical activity, healthy diet,
total cholesterol, blood pressure, fasting plasma glucose), the risk of developing
cardiovascular disease is markedly reduced. The most uncontrolled risk factor of these seven
metrics for cardiovascular health amongst US adults is healthy dietary behaviors. 73 percent
of Americans have a poor diet, and <1 percent have an ideal diet. No other metric of
cardiovascular risk comes close - by comparison, the second worst metric is body mass index
for which 31 percent have an ideal score, and the remaining five risk factors are all greater
than 40 percent with ideal control. The magnitude of the gap that needs closure is greatest
with healthy dietary behaviors, yet it frequently receives the least amount of intervention,
and the gap has worsened over the past quarter century. Fewer patients with hypertension
today are adhering to healthy nutritional habits than patients a quarter century ago. These
suboptimal dietary habits are the leading cause of mortality and disability-adjusted
life-years lost, greater than smoking, obesity, physical inactivity, high cholesterol,
hypertension, or diabetes.
Lifestyle modification is the cornerstone of cardiovascular disease prevention, and healthy
nutritional habits are essential to reducing cardiovascular risk. Changes in diet alone are
as effective as blood pressure medications, without side effects associated with
pharmacologic intervention. Increase nut consumption lowers cholesterol, and reducing
sugar-sweetened beverages reduces risk of weight gain.
More recently, greater attention has been brought to the Mediterranean diet. The
Mediterranean diet lowers blood pressure, increases HDL cholesterol, and decreases glucose
levels. The term "Mediterranean diet" was first coined by Ancel Keys, best known for the
Seven Countries Study, which found lower cardiovascular mortality in Mediterranean vs.
non-Mediterranean countries. Since Keys' seminal work, multiple observational studies and
randomized controlled trials have demonstrated a diet characterized by abundant olive oil and
nut consumption and enriched for fruits, vegetables and fatty fish to be the most likely to
reduce risk of cardiovascular events, including myocardial infarction, stroke and death. The
Mediterranean diet was speculated to have cardiovascular benefit after observational studies
suggested benefit, and the evidence solidified after randomized controlled studies showed
superiority of the Mediterranean diet in both high-risk primary prevention populations and
secondary prevention populations. The PREDIMED study showed a 30 percent reduction in major
adverse cardiovascular events, largely through a reduction in stroke, for those patients at
high risk for the development of atherosclerotic disease on a Mediterranean diet enriched for
olive oil and nut consumption. The Lyon Diet Heart Study enrolled patients after a first
myocardial infarction, and those randomized to receiving a Mediterranean diet enriched with
more bread, fish, root vegetables and fish had improved survival and fewer myocardial
infarctions than those on a usual prudent diet. Neither study demonstrated any adverse
effects of the diet. These studies, however, were conducted in Mediterranean countries, and
whether this diet can be successfully implemented in a non-Mediterranean population (and
whether the benefits would similarly translate) remains to be tested. Observational studies
suggest its possibility in a non-Mediterranean population but this finding remains to be
confirmed by randomized controlled trial.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|